Lung Cancer

Treatment with gefitinib in the adjuvant setting is associated with enhanced quality of life in patients with early-stage NSCLC and EGFR mutations.

[Fam-]trastuzumab deruxtecan shows promising clinical activity with a high and durable response rate in patients with HER2-mutated NSCLC.

Dr David Spigel reviews 5 practice-changing presentations from 2020 on the treatment of metastatic NSCLC using immunotherapy alone or in combination with chemotherapy or targeted agents.
Dr Geoff Oxnard outlines promising results from the key studies from 2020 on the neoadjuvant or adjuvant treatment of resectable and/or nonmetastatic NSCLC, as well as the value of stereotactic body radiotherapy in place of surgery during the COVID-19 pandemic.
Dr David Spigel reviews the results of key studies from 2020 on novel approaches to first- or second-line treatment of SCLC and mesothelioma with both existing and emerging agents.
Dr Geoff Oxnard provides an overview of novel approaches to metastatic NSCLC with targetable mutations, including established and newly discovered molecular targets.
Page 3 of 11
Results 21 - 30 of 107